Meeting analyst expectations typically results in a neutral short-term impact on a stock's price, as the market has likely already priced in the anticipated results. Since Neumora Therapeutics' earnings were in line with forecasts, significant price movement is less likely unless accompanied by other, more surprising news or forecasts.